Ensysce Biosciences
ENSC
8 hedge funds and large institutions have $56.4K invested in Ensysce Biosciences in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 6 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0.28% less ownership
Funds ownership: 0.39% → 0.11% (-0.28%)
33% less funds holding
Funds holding: 12 → 8 (-4)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
76% less capital invested
Capital invested by funds: $231K → $56.4K (-$175K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$11.8K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.96K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.54K |
| 4 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
+$370 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$16 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$134K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$26.2K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$20.2K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$161 |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$161 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $19.3K | +$2.96K | +184 | +18% |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $17K | -$161 | -10 | -0.9% |
|
|
3
Renaissance Technologies
New York
| $12K | +$11.8K | +730 | New |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $6.68K | +$2.54K | +158 | +60% |
|
5
BlackRock
New York
| $1.03K | – | – | – |
|
|
ASN
6
Advisory Services Network
Atlanta,
Georgia
| $368 | +$370 | +23 | New |
|
|
7
Wells Fargo
San Francisco,
California
| $25 | +$16 | +1 | +100% |
|
|
PMFA
8
Plante Moran Financial Advisors
Southfield,
Michigan
| $21 | – | – | – |
|
|
9
UBS Group
Zurich,
Switzerland
| $3 | -$161 | -10 | Closed |
|
|
SM
10
Sabby Management
Miami Beach,
Florida
| – | -$134K | -6,465 | Closed |
|
|
11
Citadel Advisors
Miami,
Florida
| – | -$26.2K | -1,274 | Closed |
|
|
TSS
12
Two Sigma Securities
New York
| – | -$20.2K | -974 | Closed |
|
13
Bank of America
Charlotte,
North Carolina
| – | -$81 | -4 | Closed |
|
|
WAM
14
Wolverine Asset Management
Chicago,
Illinois
| – | -$16 | -1 | Closed |
|
ENSC Hedge Fund Activity: Q4 2023 in Review
8 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Ensysce Biosciences (ENSC) for Q4 2023, worth a combined $56.4K — down 76% from $231K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ENSC and 2 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $11.8K. The largest seller was Sabby Management, exiting entirely with an estimated $134K sold.
- 8 institutional investors held Ensysce Biosciences (ENSC) as of Q4 2023, down from 12 in Q3 2023.
- Funds reported $56.4K of Ensysce Biosciences stock for Q4 2023, down 76% quarter-over-quarter.
- 2 funds opened new Ensysce Biosciences positions in Q4 2023 and 6 closed out, a net change of -4 holders.
- The largest Ensysce Biosciences buyer in Q4 2023 was Renaissance Technologies, an estimated $11.8K added.
- The largest Ensysce Biosciences seller in Q4 2023 was Sabby Management, an estimated $134K sold.
Based on aggregated 13F filings for Q4 2023.